John Meyers, Ph.D.

Assistant Professor of Medicine

Director of Technology

Education:

AB – Bowdoin College
PhD – Boston University School of Medicine

General field of research:

hematologic malignancies, immunological development and signaling

Other affiliations:

Director of Technology

Contact information:

Office
EBRC 413, 650 Albany Street, Boston, MA
Phone: (617) 544-7773

Lab
EBRC 420, 650 Albany Street, Boston, MA
Phone: (617) 544-7773
Fax: (617) 638-7530

johnm@bu.edu

Keywords:

Chronic lymphocytic leukemia; Cyclic nucleotide phosphodiesterases

Recent publications:

Meyers JA, Mangini AJ, Nagai T, et al. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Cytokine. 2006;35:235-246.

Alyson J. Mangini, John A. Meyers, Taro Nagai, Gijs van Seventer, and Jean Maguire van Seventer. Type I interferon regulation of Th cell responses in SLE. J. Immunol., 2007; 178: B84

Everett PC, Meyers JA, Makkinje A, Rabbi M, Lerner A. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol. 2007;82:23-30.

Mineva ND, Rothstein TL, Meyers JA, Lerner A, Sonenshein GE. CD40 ligand mediated activation of the de novo RelB NF-kappa B synthesis pathway in transformed B cells promotes rescue from apoptosis. J Biol Chem. 2007.

Meyers J.A., J. Taverna, J. Chaves, A. Makkinje, A. Lerner. 2007. PDE4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. Clinical Cancer Research 13: 4920-4927. (PMCID: PMC2656255).

Meyers J.A., D.W. Su, A. Lerner. 2009. CLL, B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors. J. Immunol 182:5400-5411. (PMCID: PMC2676892)

 

 

Technologies available for sharing upon request:

Phospho-flow cytometry